Profile

Cover photo
American Cancer Society Family of Journals
20 followers|3,772 views
AboutPostsPhotosVideos

Stream

 
According to findings published early online in Cancer, chemotherapy before or after surgery for high-risk bladder cancer improves survival, but is not routinely administered. The author conclude that patients having surgery for bladder cancer should have chemotherapy, either before or after surgery. To read this article entitled "Peri-operative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study" by Booth et al., go to http://doi.wiley.com/10.1002/cncr.28510.
1
Add a comment...
 
Study authors find that GATA3 is useful in confirming the diagnosis of metastatic urothelial carcinoma (MUC) in cytology specimens and in distinguishing between MUC and squamous cell carcinoma (SCC). p40 is a valuable adjunct to GATA3 in the diagnosis of MUC in cytology specimens. To read this article entitled “Usefulness of GATA3 and p40 immunostains in the diagnosis of metastatic urothelial carcinoma in cytology specimens” by Brandler et al., visit http://onlinelibrary.wiley.com/doi/10.1002/cncy.21424/abstract.
1
Add a comment...
 
Patients with Myc-positive or double-hit non-Hodgkin lymphoma have inferior progression-free and overall survival. In this study published early online in Cancer, the authors identify a subset of patients who achieve a complete response to induction therapy who have prolonged remission durations. Go to http://onlinelibrary.wiley.com/doi/10.1002/cncr.28642/abstract to read “Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival” by Cohen et al.

1
Add a comment...
 
Five lung cancer natural history models demonstrated that the NLST and PLCO trials have produced consistent results. The resulting models can be important tools to assess the effectiveness of lung cancer screening strategies using low-dose computed tomography. Go to http://onlinelibrary.wiley.com/doi/10.1002/cncr.28623/abstract to read “Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials” by Meza et al., published early online in Cancer.
1
Add a comment...
 
Published early online in Cancer, this review of oropharyngeal squamous cell carcinoma in the human papillomavirus (HPV) era focuses on current and investigational treatment strategies in patients with HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. Go to http://onlinelibrary.wiley.com/doi/10.1002/cncr.28595/abstract to read “What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?” by Urban et al.
1
Add a comment...
Have them in circles
20 people
Esmeralda Buchanan's profile photo
Farida Moussaoui's profile photo
Kim 0swald's profile photo
Jin Hee Kim's profile photo
Judith M. Orvos, ELS's profile photo
maggie smith's profile photo
Antonio Shaw's profile photo
James Kim's profile photo
Carissa Gilman's profile photo
 
CNCR-13-3101.R1—review article on RET gene mutations
MEN2 is a genetic syndrome caused by mutations in the RET proto-oncogene with different penetrance producing 3 variants, MEN2A, MEN2B, and FMTC. The discovery of RET mutations that cause MEN2 lead to the development of genetic testing that enabled personalized approaches to diagnosis, risk stratification, and appropriate treatment. Go to http://onlinelibrary.wiley.com/doi/10.1002/cncr.28661/abstract to read “RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma” by Krampitz and Norton.

1
Add a comment...
 
In this analysis published early online in Cancer, the cause and timing of death in a large cohort of long-term survivors of head and neck squamous cell carcinoma was evaluated. Through use of a competing risk model, varying risk of death was identified based on demographic and clinical factors including age, primary site of disease, and race. Go to http://onlinelibrary.wiley.com/doi/10.1002/cncr.28588/abstract to read “Causes of death in long-term survivors of head and neck cancer” by Baxi et al.
1
Add a comment...
 
In this single-arm, phase 2 trial published early online in Cancer, ramucirumab monotherapy had a limited impact on the RECIST-defined response of patients with mRCC who either had progression on or developed drug intolerance to VEGFR inhibitory tyrosine kinase inhibitors. However, the median and 1-year progression-free survival rates were encouraging, and ramucirumab was safe and well tolerated. Go to http://onlinelibrary.wiley.com/doi/10.1002/cncr.28634/abstract to read “A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy” by Garcia et al.
1
Add a comment...
 
Four new therapies have been approved by the US FDA from 2011-2013 for the treatment of metastatic melanoma, yet there are little data to guide sequencing of these therapies. In a retrospective analysis published early online in Cancer, immunotherapy does not alter treatment effect of the BRAF inhibitor vemurafenib and treatment with an immunotherapeutic, ipilimumab, is not effective following prior therapy with vemurafenib in patients with BRAF-mutant, metastatic melanoma. Go to http://onlinelibrary.wiley.com/doi/10.1002/cncr.28620/abstract to read “Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors ” by Ackerman et al.
1
Add a comment...
 
Fine needle aspiration is the dominant modality for diagnosing thyroid nodules. Certain follicular cell-derived thyroid carcinomas have been shown to have a worse prognosis, and these are termed “aggressive variants” of thyroid carcinomas. The salient cytomorphologic features of these “aggressive variants” are described in this review entitled “Aggressive variants of follicular cell-derived thyroid carcinomas: A cytopathologist's perspective” by Lastra et al., found at http://onlinelibrary.wiley.com/doi/10.1002/cncy.21417/abstract.
1
Add a comment...
Story
Tagline
Content from the American Cancer Society family of journals.
Introduction
From groundbreaking findings to insightful reviews, the American Cancer Society's family of journals continues to fuel new discoveries in cancer research and guide clinical practice around the world.